Pain Therapeutics
16
0
0
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 16 trials
100.0%
+13.5% vs industry average
6%
1 trials in Phase 3/4
13%
2 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
Role: lead
A Safety Study of PTI-125 in Healthy Volunteers
Role: lead
Nasal Human Abuse Potential of PTI-821
Role: lead
Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse
Role: lead
Abuse Potential Study of PF-00345439
Role: lead
Effects of Ethanol on Oxycodone Pharmacokinetics in Healthy Volunteers
Role: lead
Dose Proportionality Study Of PF-00345439 Formulation Under Fed Conditions
Role: lead
Effects of Food on Oxycodone Pharmacokinetics in Healthy Volunteers
Role: lead
Single-Dose, Crossover Study To Compare Bioavailability Of Two Formulations Under Fed And Fasted Conditions
Role: lead
Long-term Safety of PF-00345439 (Oxycodone)
Role: lead
Pharmacokinetics And Relative Bioavailability Study Of Oxycodone
Role: lead
A Study To Characterize The Pharmacokinetics Of Oxycodone In Healthy Volunteers
Role: lead
Food Effect And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers
Role: lead
Pharmacokinetics And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers
Role: lead
Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma
Role: lead
Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma
Role: lead
All 16 trials loaded